A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

Tirzepatide could result in net lifetime health care costs of more than $16 trillion in the U.S. if all people eligible to ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di ...

Tirzepatide and semaglutide are type 2 diabetes drugs that are often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

Among people with obesity or overweight, tirzepatide users lost 20.2% of body weight compared with a 13.7% loss with semaglutide over 72 weeks. Participants on tirzepatide also lost 5.4 cm more in ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide ...

Switching to tirzepatide also led to a weight loss of 10.5 kg (23.1 lb) compared with 3.6 kg (7.9 lb) with the higher dulaglutide dose (P<0.001), according to Liana Billings, MD, of the University ...

Of the 751 people in the study, half took tirzepatide and half took semaglutide. Both groups received weekly shots for 72 weeks, using the highest dose they could handle without strong side effects.

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

Patients (N=1,999,881) diagnosed with AF between 2022 and 2024 and who used tirzepatide for diabetes and/or overweight or obesity (n=10,693) were eligible for this study.